PUNE, India, September 19, 2016
PUNE, India, September 19, 2016 /PRNewswire/ --
ReportnReports.com adds "Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016" to its store. The report provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)'s therapeutic pipeline with comprehensive information on the therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and special features on late-stage and discontinued projects.
Complete report on H2 2016 pipeline review of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) with 66 market data tables and 16 figures, spread across 376 pages is available at http://www.reportsnreports.com/reports/682605-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-pipeline-review-h2-2016.html.
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.
It also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 20, 24 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 5, 1 and 2 molecules, respectively.
Companies discussed in this 4SC AG, AbbVie Inc, Acetylon Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., ADC Therapeutics Sarl, Affimed GmbH, Amgen Inc., Arno Therapeutics, Inc., Bellicum Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, Gamida Cell Ltd., Incyte Corporation, Merck & Co., Inc., Merck KGaA, Mesoblast Limited, Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc., Molecular Templates Inc., NantKwest, Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Philogen S.p.A., Polyphor Ltd., Rich Pharmaceuticals, Inc., Seattle Genetics, Inc., Selvita S.A., Sigma-Tau S.p.A., Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited, TG Therapeutics, Inc., Theravectys SA, TRACON Pharmaceuticals, Inc. and Trillium Therapeutics Inc.
Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=682605. (This is a premium report priced at US$2000 for a single user License.)
Drug Profiles mentioned in this research report are (INCB-039110 + INCB-040093), ADCT-301, AFM-13, Alocrest, AR-42, avelumab, azacitidine, balixafortide, BC-8Y90, BMS-986016, BPX-501, brentuximab vedotin, CBM-C30.1, Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma, Cellular Immunotherapy for Oncology, Cellular Immunotherapy for Oncology, Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas, Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas, Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia, Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer, Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection, Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases, Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology, CMD-003, CPI-0610, CUDC-907, Epstein-Barr virus vaccine, Ferritarg, FP-1305, haNK Program, ibrutinib, INCB-40093, Indimitecan, Indotecan hydrochloride, Iomab-B, ipilimumab, ixazomib citrate, lirilumab, MK-2206, mocetinostat, Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections, MPC-CBE, MT-17000, NiCord, nivolumab, NL-101, ONX-0801, pembrolizumab, PF-06801591, PNK-007, procarbazine hydrochloride, radretumab, resminostat, ricolinostat, RP-323, ruxolitinib phosphate, sapanisertib, SEA-CD40, SEL-24B489, SL-101, SL-501, Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma, temsirolimus, TGR-1202, TRC-102, TTI-621, Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma and vinorelbine tartrate.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Another newly published market research report titled on Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016 provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. Companies discussed in this research report are Alcobra Ltd, Amarantus Bioscience Holdings, Inc., APeT Holding BV, Arbor Pharmaceuticals, LLC, BCWorld Pharm Co. Ltd., BioLite, Inc., Collegium Pharmaceutical, Inc., Curemark, LLC, DURECT Corporation, Egalet Corporation, Eli Lilly and Company, Ensysce Biosciences Inc., H. Lundbeck A/S, Heptares Therapeutics Limited, Highland Therapeutics, Inc., Integrative Research Laboratories Sweden AB, Intra-Cellular Therapies, Inc., INVENT Pharmaceuticals, Inc., KemPharm, Inc., Luc Therapeutics, Inc., Medgenics, Inc., Merck & Co., Inc., Neos Therapeutics, Inc., NeuroDerm Ltd., Neurovance, Inc., NLS Pharma Group, Noven Pharmaceuticals, Inc., P2D Bioscience, Polleo Pharma Limited, Reviva Pharmaceuticals Inc., Shire Plc , Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd. and TRImaran Pharma, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Pipeline market research report of 198 pages is available at http://www.reportsnreports.com/reports/682609-attention-deficit-hyperactivity-disorder-adhd-pipeline-review-h2-2016.html.
Explore more reports on Pharmaceuticals
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE ReportsnReportsPR Newswire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.